Tag: AstraZeneca

EU Advisors Recommend AstraZeneca and Merck’s Tablets

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positi...

Big Pharma Answered for High Prices

U.S. senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at a Senate...

AZ Drug Reduces MACE in Cases with No Prior Heart Attack

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major...

AZ and MSD’s Drug Delays Pancreatic Cancer Progression

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced positive results from the Phase III POLO trial. Results from the trial ...

NeoTX in Clinical Collaboration with AstraZeneca

astrazeneca
NeoTX Therapeutics, Ltd announced that it has entered into a clinical collaboration with AstraZeneca Group Plc global biologics research and development arm, MedImmune, to support Phase 1b/2 studies i...

Big Pharma to Testify in High Drug Pricing Case

While congressional scrutiny on drug pricing is nothing new, the prospect of some of the pharmaceutical industry's highest-profile CEOs testifying on the issue will make for a must-watch event. In ...

BTD for AstraZeneca’s LRTI Drug

AstraZeneca’s MEDI8897 has secured breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for the prevention of lower respiratory tract infection (LRTI) caused by respir...

EMA Recommended AstraZeneca’s Type I Diabetes Drug

AstraZeneca’s Forxiga (dapagliflozin) has been recommended by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) as an oral adjunct treatment to insulin i...

AstraZeneca and Aptamer Group to Develop Targeted Kidney Delivery

Biotechnology company Aptamer Group is collaborating with AstraZeneca to develop drug delivery devices targeting the kidney. The two-year project will see AstraZeneca exploring the use of aptamer t...

Sobi Got Rights for AstraZeneca’s Drug

Swedish Orphan Biovitrum AB (Sobi) has completed the acquisition of US rights of Synagis (palivizumab) from AstraZeneca in a deal valued at around $1.6bn. The deal also provides Sobi with the right...

Big Pharma’s Experts Go to Biotech

Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZeneca. Vo...

Companies with Most FDA Approvals

In 2018, the U.S. Food and Drug Administration (FDA) approved 59 novel drugs, meaning approved new molecular entities (NMEs). The figure for 2017 was 46 novel drugs. The FDA notes, “Each year, CDER a...

AstraZeneca and Ironwood’s IBS-C Drug Approved in China

Ironwood Pharmaceuticals’ irritable bowel syndrome treatment Linzess has gained approval in China, opening up a market of up to 14m adults with the condition. The good news coincides with big chang...

Shake-up in AstraZeneca

British pharma giant has aligned therapy R&D units to new commercial strategy and hired oncology expert Jose Baselga to lead new phase in development. AstraZeneca has announced a major shake-up...

Flu Vaccines Effectiveness Research

The quadrivalent live attenuated influenza vaccine (LAIV4) is less effective than inactivated influenza vaccine (IIV) against influenza A/H1N1pdm09 in all pediatric age groups, according to research p...

NICE Recommends AstraZeneca’s Asthma Treatment

NICE has recommended the use of AstraZeneca’s severe asthma treatment Faserna (benralizumab) after the company revised its initial pricing offer. The recommendation from England's cost effectivenes...